These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 24446062

  • 1. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
    Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, Zhang Y, Gotou H, Lefkowitz M, Zhang J.
    Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
    Supasyndh O, Wang J, Hafeez K, Zhang Y, Zhang J, Rakugi H.
    Am J Hypertens; 2017 Nov 06; 30(12):1163-1169. PubMed ID: 28992296
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
    Wang JG, Yukisada K, Sibulo A, Hafeez K, Jia Y, Zhang J.
    J Hypertens; 2017 Apr 06; 35(4):877-885. PubMed ID: 28030431
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
    Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W.
    J Clin Hypertens (Greenwich); 2019 Jan 06; 21(1):67-76. PubMed ID: 30536595
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
    Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, Akahori M, Zhang J.
    Hypertens Res; 2015 Apr 06; 38(4):269-75. PubMed ID: 25693859
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.
    Izzo JL, Zappe DH, Jia Y, Hafeez K, Zhang J.
    J Cardiovasc Pharmacol; 2017 Jun 06; 69(6):374-381. PubMed ID: 28338503
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
    Kusaka H, Sueta D, Koibuchi N, Hasegawa Y, Nakagawa T, Lin B, Ogawa H, Kim-Mitsuyama S.
    Am J Hypertens; 2015 Dec 06; 28(12):1409-17. PubMed ID: 25762811
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials.
    Geng Q, Yan R, Wang Z, Hou F.
    Cardiology; 2020 Dec 06; 145(9):589-598. PubMed ID: 32726791
    [Abstract] [Full Text] [Related]

  • 18. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
    Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators.
    Lancet; 2012 Oct 20; 380(9851):1387-95. PubMed ID: 22932717
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs.
    Han Y, Zhou Y, Na J, Li F, Sun Y.
    Am J Hypertens; 2023 Nov 15; 36(12):643-650. PubMed ID: 37596996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.